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Abstract
Recent studies have revealed that differentiated epithelial cells would acquire stem cell-like and tumorigenic properties
following an Epithelial-Mesenchymal Transition (EMT). However, the signaling pathways that participate in this novel
mechanism of tumorigenesis have not been fully characterized. In Runx32/2p532/2 murine gastric epithelial (GIF-14) cells,
EMT-induced plasticity is reflected in the expression of the embryonal proto-oncogene Hmga2 and Lgr5, an exclusive
gastrointestinal stem cell marker. Here, we report the concurrent activation of an EGFR/Ras gene expression signature
during TGF-b1-induced EMT in GIF-14 cells. Amongst the altered genes was the induction of Egfr, which corresponded with
a delayed sensitization to EGF treatment in GIF-14. Co-treatment with TGF-b1 and EGF or the expression of exogenous KRas
led to increased Hmga2 or Lgr5 expression, sphere initiation and colony formation in soft agar assay. Interestingly, the gain
in cellular plasticity/tumorigenicity was not accompanied by increased EMT. This uncoupling of EMT and the induction of
plasticity reveals an involvement of distinct signaling cues, whereby the EGFR/Ras pathway specifically promotes stemness
and tumorigenicity in EMT-altered GIF-14 cells. These data show that the EGFR/Ras pathway requisite for the sustenance of
gastric stem cells in vivo and in vitro is involved in the genesis and promotion of EMT-induced tumor-initiating cells.
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Introduction
Epithelial-Mesenchymal Transition (EMT) is a developmental
program that plays an instrumental role in early embryo
patterning during gastrulation [1]. During EMT, epithelial cells
are temporarily reprogrammed to lose their defining features such
as cell-cell adhesion, epithelial tight junction and desmosomes.
Concurrently, there is a gain of mesenchymal properties, including
increased cell migration and resistance to anoikis. These profound
changes reflect a highly coordinated genetic reprogramming
effected by specialized transcription factors, such as Snail, Twist
and Zeb, that are activated in response to extracellular cues, most
notably Transforming Growth Factor beta (TGF-b) [1].
TGF-b is a pleiotropic growth factor that also mediates tumor
suppressive effects in multiple adult tissues. Components of the
TGF-b pathway are frequently targeted by mutations in human
carcinomas [2]. However, in advanced cancer the TGF-b pathway
is paradoxically a major driver of tumor progression and
metastasis due in part to its aberrant activation of EMT [1].
More recently, evidence have emerged that the aberrant induction
of EMT endows cellular plasticity and stem-like properties in
differentiated mammary epithelial cells, giving rise to so-called
cancer stem cells [3,4]. Intriguingly, these metastable mesenchy-
mal and stem cell-like states could be established solely by
paracrinal and autocrinal signals, specifically the TGF-b and the
canonical and non-canonical Wnt pathways [5]. Notably, these
pathways feature prominently in the self-renewal of the mammary
epithelium, implicating a common mechanism in maintaining the
epigenetic states of normal and cancer stem cells.
In the gastrointestinal epithelium, the stem cells at the base of
the pyloric gastric glands and intestinal crypts are similarly reliant
on an active and dynamically regulated Wnt pathway [6,7]. This
dependency is reflected in the exclusive expression of Lgr5, which
functions to amplify the Wnt signal in these stem cells [8,9]. In
addition to Wnt, a delicate balance of BMP, Notch and Epidermal
Growth Factor (EGF) signaling within the intestinal stem cell niche
is crucial to the maintenance of the stem cell state [10–14]. During
injury, modulation of the Wnt signal would induce a state of
plasticity in a specific subset of progenitor cells, enabling their
dedifferentiation to replace damaged Lgr5+ve stem cells [15]. The
induction of a stem cell state in differentiated cells in response to
damage and increased Wnt signal in the intestinal crypt parallels
the aforementioned observations in mammary epithelial cells,
which together suggest a role for induced plasticity under
physiological conditions and during carcinogenesis. This is
supported by the participation of Lgr5 in supporting Wnt-driven
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intestinal adenomas in mouse, and cancer stem cells isolated from
primary human colon tumors [16,17].
In a previous study, we observed in an immortalized Runx32/2
p532/2 gastric epithelial (GIF-14) cell line a stem-like and
tumorigenic subpopulation that arose from spontaneous EMT
[18]. The acquisition of cellular plasticity following EMT is
reflected in the elevated expression of stem cell-associated markers
Lgr5, Sox9 and Hmga2. In contrast, Runx3+/+p532/2 cells are
resistant to EMT, demonstrating a safeguarding role for Runx3,
which is an established gastric tumor suppressor [19,20]. A
primary driver of EMT in GIF-14 is the TGF-b pathway, as
treatment with exogenous TGF-b1 or pharmacological inhibition
of TGF-bRI readily induced interchangeable mesenchymal- and
epithelial-like states, respectively [18]. Here, we demonstrate that
while the TGF-b pathway is crucial in initiating EMT, other
physiologically relevant pathways participate in promoting plas-
ticity and a stem cell-like state in GIF-14 cells. In particular, we
observed the activation of an EGFR/Ras gene expression
signature during TGF-b1-induced EMT in GIF-14 cells, which
included increased Egfr expression. This endowed GIF-14 cells
increased responsiveness to EGF, which acted in concert with
TGF-b1 to activate Hmga2 expression. Consistent with this
cooperation, pharmacological inhibition of MEK, a downstream
effector of EGFR, effectively blocked TGF-b1-activated Hmga2
expression. A functional contribution of the Ras pathway to
stemness and tumorigenicity of GIF-14 cells was further demon-
strated in the increased sphere initiation and colony formation in
response to exogenous KRas. Surprisingly, the KRas-induced
stemness and tumorigenicity were not accompanied by increased
EMT in GIF-14. Together, these data reveal a novel relationship
between two physiologically important signals in the induction and
maintenance of a stem-like state in gastric epithelial cells.
Results
An EGFR/RAS gene expression signature corresponds
with TGF-b1-induced EMT in GIF-14 cells
In a previous study, it was observed that GIF-14 cells readily
undergo EMT upon treatment with TGF-b1, giving rise to a
tumorigenic, stem-like subpopulation. To elucidate the gene
expression changes that precede this phenomenon, the pre-
EMT, epithelial subpopulation of GIF-14 cells was fractionated
and treated with TGF-b1 and subjected to expression microarray
analyses. These revealed that 2135 genes were significantly altered
within 24 h post-TGF-b1 treatment. In addition to changes in
genes associated with TGF-b and EMT, Gene Set Enrichment
Analysis (GSEA) revealed a significant enrichment of gene sets
belonging to the Epidermal Growth Factor Receptor (EGFR) and
RAS pathways (Figure 1A). Amongst the most prominent leading-
edge genes enriched within the EGFR/RAS gene sets were Egfr,
KRas and Lrig1 (Figure 1B & 1C). Egfr and KRas are molecular
switches responsible for the activation of EGFR/RAS pathways,
while Lrig1 is a pan-negative regulator of ErbB pathways,
including EGFR pathway [21]. Perturbation of the expression of
these genes by TGF-b1 treatment suggests a cross-talk between
TGF-b1 and EGFR/RAS pathways. The induction of Egfr levels
by TGF-b1 treatment observed in the microarray analyses was
subsequently confirmed by qRT-PCR, which showed that Egfr
expression was induced in GIF-14 cells within 24 h of TGF-b1
treatment and persisted for at least 48 h (Figure 1D & 1E). To
further validate this at the level of protein expression, Western
blotting of Egfr protein was performed on TGF-b1-treated GIF-14
cells using two independent anti-Egfr antibodies (Figure 1F).
Although the increase in Egfr protein expression in this
experiment is relatively modest, densitometric measurement of
band intensities confirm the induction of Egfr expression by TGF-
b1 (Figure 1G). To determine if the increased Egfr expression
translates into an activation of the EGFR/Ras signaling pathway,
the phosphorylation of Egfr at tyrosine residues 1068 and 1092
and Extracellular signal-Regulated Kinase (Erk) 1/2 were
measured by Western blotting using pEgfrY1068/1092- and
pErk1/2 -specific antibodies. This revealed a transient induction
of Egfr within 24 h of TGF-b1 treatment, which was accompanied
by a clear increase of pErk1/2. However, the level of pEgfrY1068/1092
remained unchanged, suggesting the involvement of an alterna-
tive mechanism that is independent of phosphorylation at the two
residues studied (Figure 1H). Interestingly, while the induction of
Egfr expression was robust in this experiment, it was not
sustained as that shown in Figure 1F, indicating that Egfr is
tightly regulated by negative feedback mechanisms, such as that
involving Lrig1 [21].
TGF-b1 cooperates with EGF in inducing stemness in GIF-
14 cells
In GIF-14 cells, the entrance into EMT is marked by increased
expression of EMT-inducing transcription factors Snai1, Snai2 and
Twist1; mesenchymal markers vimentin (Vim), fibronectin1 (Fn1) and
N-cadherin (N-cad); and stemness markers Lgr5 and Hmga2 [18].
To investigate the involvement of EGFR and other signaling
pathways known to induce EMT, GIF-14 cells were treated with
EGF, Fibroblast Growth Factors (FGF) 2 and 10, and Hepatocyte
Growth Factor (HGF) and TGF-b1. Changes in the expression of
EMT/Stemness gene signature were measured by qRT-PCR. The
results confirm that TGF-b1 is a major driver of EMT in GIF-14
cells while the other growth factors did not promote EMT (Figure
S1). However, EGF further augmented TGF-b1’s induction of
Hmga2 a marker of stemness and plasticity [22–24] (Figure S1). To
investigate this further, GIF-14 cells were treated with EGF and
TGF-b1 separately or in combination for 15 h. Gene expression
analysis confirms the cooperation between TGF-b1 and EGF on
the induction of Hmga2. However, EGF did not cooperate with
TGF-b1 on the induction of all EMT markers tested (Figure 2A).
As the induction of Egfr occurred after 24 h of TGF-b1
treatment, we next sought to determine if the observed cooper-
ation between TGF-b1 and EGF is dependent on the duration of
TGF-b1 treatment. To do this, GIF-14 cells were subjected to
varying periods of TGF-b1 treatment before treatment with EGF
for 15 h. This revealed increased cooperation between TGF-b1
and EGF in the induction of Hmga2 upon extended exposure to
TGF-b1 (Figure 2B). The stronger EGF responsiveness on Hmga2
corresponded well with elevated Egfr expression in response to
TGF-b1, which peaked at 24 h. In addition, TGF-b1 also induced
a delayed kinetics on Lrig1, which is a negative regulator of EGFR
signaling important to the maintenance of gastrointestinal stem
cells [12,21]. The induction of Lrig1 is concordant with the
diminished EGF-responsiveness of Hmga2 observed at later time
points [21]. Consistent with the earlier observation, the cooper-
ation between TGF-b1 and EGF was absent for Snai1 and Fn1,
two well-defined markers of TGF-b/Smad-induced EMT
(Figure 2B). Therefore, these data suggest that the TGF-b1
pathway employs the EGF pathway to specifically induce stemness
and plasticity, but not EMT.
To further characterize the contribution of EGFR signaling to
cellular plasticity, resting and TGF-b1-activated GIF-14 cells were
treated with inhibitors of TGF-bRI (SB431542), EGFR (AG1478)
and MEK1/2 (U0126), which is a major effector of the EGFR/
Ras pathway. The treatment of all three inhibitors resulted in a
strong blockade of TGF-b1 induction of Hmga2, confirming the
TGF-b-Induced Stemness Is Mediated via EGFR/Ras
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participation of EGFR pathway, in particular the Ras/MEK
signaling axis (Figure 2C). Furthermore, these inhibitors greatly
suppressed basal expression levels of Hmga2 and Lgr5, revealing a
contribution of the EGFR pathway in the maintenance of cellular
plasticity in GIF-14 cells (Figure 2C). In sharp contrast, the
activation of Snai1 by TGF-b1 treatment was inhibited only by
SB431542, and not the inhibitors of the EGFR/MEK pathway
(Figure 2C). These observations provide compelling evidence that
the induction of stemness and plasticity by TGF-b1 is mediated
through the EGFR/Ras/MEK signaling axis.
It has been reported that TGF-b can directly transactivate the
EGFR to effect a change in ERK phosphorylation, which is a
major downstream effect of Ras activation [25]. To determine if
this direct mechanism is involved, the effects of TGF-b1 on the
Figure 1. TGF-b1 induces EGFR/Ras gene expression signature. (A) A heat map highlighting the results of gene set enrichment analysis of
genes significantly altered by TGF-b1 (2.5 ng/ml) in GIF-14 cells (nominal p-values,0.05). Mean gene expression value of leading-edge genes of each
gene set is plotted. Lower levels of expression are represented in green and higher expression in red. Gene sets representing differentially enriched
pathways are grouped. (B) The Enrichment Plot of a representative EGFR gene set. The relative gene positions of gene set are indicated by the vertical
lines (middle) under the graph, which presents the enrichment scores of individual genes (top). Lines clustered to the left represent higher ranked
genes in the ranked list. Bottom plot displays the rank matrix of these genes. The position of leading-edge genes suggests a positive correlation
between TGF-b1 treatment and EGFR pathway. (C) A heat map depicting the expression levels of genes within the EGFR gene set in response to 24 h
of TGF-b1 treatment, as measured by expression microarray analysis. Each column represents the expression data derived from a single replicate
(n = 3). Gene expression is normalized for each row; where lower levels of expression are represented in shades of blue and higher expression in red.
The arrow highlights an induction of Egfr mRNA in response to TGF-b1. (D) Normalized Egfr mRNA expression level as measured by microarray. (E)
Validation of TGF-b1 induction of Egfr expression by quantitative PCR. Expression of Egfr are normalized against that of Gapdh and expressed relative
to the untreated control (means6 SEM, n= 4). Student’s t-tests are performed and double asterisks represent p-value,0.01. (F) Western blot analysis
of total Egfr expression as measured by two separate Egfr-specific antibodies – Ab #1 (Abcam) and Ab #2 (Cell signaling). The expression level of a-
tubulin is used as a control for the amounts of protein lysates loaded. (G) Protein band intensities are assessed by densitometric analysis. The band
intensities of Egfr in Figure 1F were sampled three times and normalized against that of a-tubulin (means 6 SEM, n= 3). Student’s t-tests are
performed in which single and double asterisks denote p value,0.05 and p value,0.01, respectively. (H) Western blot analysis of phosphorylated Egfr
and Erk expression in response to TGF-b1 treatment. GIF-14 cells were treated with TGF-b1 (2.5 ng/ml) for 24 h and 48 h before harvesting for
Western blotting. Phosphorylation of Egfr at tyrosine residues 1068 and 1092 and Erk1/2 was detected by pEgfrY1068/1092- and pErk1/2–specific
antibodies. Total Egfr expression levels were measured using anti-Egfr antibody #2 as shown in Figure 1F. Immunoblots of a-tubulin serves as a
control for the amount of proteins loaded.
doi:10.1371/journal.pone.0070427.g001
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phosphorylation states of Egfr and Erk1/2 in the immediate time
scale were determined by Western blotting. This revealed that
TGF-b1 rapidly induced a rapid dephosphorylation of Erk1/2
within 15 min, which was recovered after 120 min (Figure 2D, top
panel). This was markedly different to the effect of EGF
(Figure 2D, bottom panel), which rapidly induced Erk1/2
phosphorylation. A further difference could be observed in the
induction of phosphorylated EgfrY1068 and EgfrY1092 by EGF,
which is absent in the case of TGF-b1 treatment. Taken together,
these data suggest that the transactivating activity of TGF-b1 on
Figure 2. TGF-b and EGFR pathways cooperate to induce stemness in GIF-14 cells. (A) Changes in the expression of stemness- and EMT/
mesenchymal-associated marker genes in response to TGF-b1 and EGF. GIF-14 cells were treated with murine EGF (10 ng/ml) or TGF-b1 (2.5 ng/ml) or
in combination for 15 h. Quantitative PCR measurements of gene expression levels are normalized against Gapdh levels, and expressed relative to the
control sample (means 6 SEM, n = 4). Student’s t-tests are performed in which single and double asterisks denote p value,0.05 and p value,0.01,
respectively and n.s represents not significant (Black bracket: TGF-b1 responsiveness; Red bracket: cooperative induction by TGF-b1 and EGF). (B)
Cooperative induction of stemness by EGF and TGF-b1. GIF-14 cells were pretreated with TGF-b1 (2.5 ng/ml) for varying periods at 15 h, 24 h, 48 h
and 72 h before the addition of murine EGF (10 ng/ml) for another 15 h. Changes in the mRNA levels of stemness marker Hmga2, regulators of EGF
signaling EGFR and Lrig1, EMT markers Snai1 and fibronectin1 (Fn1) were determined by qRT-PCR. The values are normalized against those of Gapdh
and are expressed relative to that of the control (means 6 SEM, n = 3). Student’s t-tests are performed where indicated. Single and double asterisks
represent p value,0.05 and p value,0.01, respectively while n.s denotes not significant (Black bracket: TGF-b1 responsiveness; Blue bracket: EGF
responsiveness; Red bracket: cooperative induction by TGF-b1 and EGF). (C) TGF-b1 induction of Hmga2 is abrogated by inhibitors of EGFR and MEK1/
2. GIF-14 cells were treated with SB431542 (TGF-bRI inhibitor; 10 mM) or AG1478 (EGFR inhibitor; 10 mM) or U0126 (MEK1/2 inhibitor; 10 mM) or in
combination with TGF-b1 (2.5 ng/ml) for 48 h. Changes in the mRNA levels of stemness marker Hmga2 and EMT marker Snai1 were ascertained by
qRT-PCR and normalized values are expressed relative to the control values (means 6 SEM, n = 4). Student’s t-tests are performed where indicated.
Single and double asterisks denote p value,0.05 and p value,0.01, respectively. (D) The effects of TGF-b1 and EGF on the phosphorylation states of
Egfr and Erk. GIF-14 cells were treated with TGF-b1 (2.5 ng/ml; top panel) or murine EGF (10 ng/ml; bottom panel) for various short periods of time
from 15 to 120 min. The expression levels of phosphorylated Egfr at tyrosine residues 1068 and 1092 and Erk1/2 were measured by Western blot
analysis using pEgfrY1068/1092- and pErk1/2–specific antibodies Total Egfr expression was determined using anti-Egfr antibody #2 as shown in
Figure 1F. The expression level of a-tubulin serves as a control for the amount of proteins loaded.
doi:10.1371/journal.pone.0070427.g002
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the EGFR pathway does not account for the observed induction of
the EGFR/Ras gene expression signature in GIF-14 cells. Instead,
it was likely mediated via secondary events, such as the induction
of Egfr expression (Figure 1F and 2B).
Activation of Ras in GIF-14 induces a stem cell-like state
but not EMT
The activation of Ras is a major downstream event following
the binding of EGF to its receptor. To further establish an
involvement of the Ras pathway in EMT-induced stemness,
inducible GIF-14 lines were generated in which the expression of
wild type (KRasWT) or a constitutively active mutant form of
KRas (KRasV12) could be induced by the withdrawal of
doxycycline from the culture medium. Quantitative RT-PCR
measurement of changes in gene expression showed that the
expression of both wild type and mutant KRas in GIF-14 cells for
48 h led to the clear induction of Hmga2, as well as the
gastrointestinal stem cell marker Lgr5 (Figure 3A).
Concordant with earlier observations, the activation of the Ras
pathway did not alter the expression of relevant EMT markers in
GIF-14 cells (Figure 3A). This is supported by Western blotting
analysis, which showed that the expression level of Vimentin
remained unchanged following the expression of oncogenic
KRasV12 (Figure 3B). Similarly, the expression level of E-
cadherin (E-Cad) was maintained at a consistent level, in keeping
with the mRNA expression pattern (Figure 3B and 3A).
Furthermore, the induction of KRasV12 did not significantly
alter cell morphologies, compared with the induction of fibroblast-
like morphologies by TGF-b1, which is a hallmark of EMT
(Figure 3C). Lastly, the induction of KRasV12 did not significantly
increase the migratory properties of GIF-14 cells in wound healing
assays (Figure 3D and E). Together, these data suggest that the
Ras pathway act to specifically promote stemness/plasticity
without affecting the epithelial-mesenchymal states of GIF-14 cells.
Activation of Ras pathway functionally promotes sphere
formation and tumorigenicity
To functionally assay Ras-induced stemness and plasticity, GIF-
14/KRasV12 cells were subjected to serum-free sphere culture in
low attachment tissue culture substratum. The importance of the
EGFR signal in this assay has been previously established in that
exogenous EGF is necessary for the generation of GIF-14 spheres
(data not shown). Accordingly, the activation of the Ras pathway
in GIF-14/KRasV12 cells following the withdrawal of doxycycline
significantly promoted sphere formation and growth. These
enhancements were completely abolished with the blocking of
MEK1/2 by U0126 (Figure 3F & 3G), consistent with the efficacy
of this inhibitor in inhibiting MEK1/2 (Figure S2). Indeed,
treatment with U0126 reduced sphere initiation to levels lower
than that of the control (uninduced) sample, attesting to the
contribution from the exogenous EGF in the culture medium
(Figure 3F & 3G). Interestingly, despite the absence of exogenous
TGF-b1 in the sphere culture, SB431542 partially reduced the
effect of Ras, suggesting the involvement of autocrinal TGF-b in
sphere formation (Figure 3F & 3G).
It was shown that the sphere-forming population in the parental
GIF-14 line was also the tumorigenic fraction [18]. Therefore,
GIF-14/KRasV12 cells were cultured in soft agar to measure
anchorage-independent growth, an indicator of tumorigenicity.
Consistent with the increase in stemness, a strong increase in
anchorage-independent growth following the induction of
KRasV12 was observed in these cells when plated in two different
densities (Figure 3H & 3I; data not show). Together, these results
indicate that the Ras pathway plays a significant role in promoting
stemness and tumorigenicity in GIF-14 cells.
Discussion
In recent years, the phenomenon of somatic reprogramming
and induced pluripotency has shed new light into the plasticity and
dedifferentiation associated with cancer [26,27]. Similarly, the
passage of differentiated cells through an EMT induces pheno-
typically plastic and multipotent ‘‘cancer stem cells’’. These
observations hold implications on the cell-of-origin of cancer
[28]. Indeed, experimental evidence suggests that in addition to its
role in cancer progression, EMT-induced plasticity promotes
tumor initiation [29]. Therefore, understanding the factors that
afford such plasticity, particularly the paracrinal signals involved in
the maintenance of normal and cancer stem cells, is of interest.
The loss of the tumor suppressor gene Runx3 is an early event
during gastric carcinogenesis [19,20]. In a previous study,
immortalized Runx32/2p532/2 gastric epithelial cells that have
undergone spontaneous EMT was reported to be endowed with
stem-like and mesenchymal properties and increased tumorige-
nicity [18]. The increase in cellular plasticity was reflected in a
mesenchymal-like state and the reactivation of a number of stem
cell markers, most notably Hmga2 and Lgr5. However, the delayed
kinetics of their reactivation suggested the involvement of
intermediate events. In elucidating the signaling pathway under-
lying this phenomenon, the current study reveals that TGF-b1
induces stemness and plasticity by utilizing the EGFR/Ras
signaling pathway, with the specific activation of Hmga2, a non-
histone component of the chromatin associated with stemness,
plasticity and tumorigenicity [22–24,30,31]. Treatment of pre-
EMT GIF-14 cells with TGF-b1 triggered an EGFR/Ras gene
expression signature that arose concurrently with the initiation of
EMT. This phenomenon corresponded with an induction of Egfr
expression that sensitized GIF-14 cells to the induction of Hmga2
by EGF.
TGF-b was originally described and named for its ability to
mediate the phenotypic transformation of normal rat kidney
fibroblast [32]. This property was subsequently found to be
dependent on the activation of EGFR by TGF-a or EGF [33,34].
Although the engagement of EGFR to its ligands is known to
activate several divergent downstream pathways, the activation of
Hmga2 by TGF-b1 in the GIF-14 cell model is effectively blocked
by a pharmacological inhibitor to MEK1/2, indicating the
participation of the Ras-MEK signaling axis. This involvement
was confirmed in the induction of Hmga2 and Lgr5 by exogenous
wild type or oncogenic KRas in GIF-14/KRasWT and GIF-14/
KRasV12 inducible lines, respectively. Importantly, the EGFR/
Ras/MEK signal functionally supported in GIF-14 cells the
generation of spheres, an in vitro assay of stemness; as well as
increased colony formation in soft agar assay, a classical assay of
cellular transformation and tumorigenicity. Together, these data
support a model in which TGF-b1-induced EMT is accompanied
by an activation of the EGFR/Ras/MEK signaling pathway via
increased Egfr expression; which in turn drives a stem-like and
tumorigenic state in GIF-14 cells, as depicted in Figure 4. While
the data presented in this study were derived from in vitro
experiments, the in vivo relevance of this relationship could be
appreciated in the recent report that the targeting of Lrig1, a
negative regulator of Egf/ErbB receptor signaling, in a Lrig1+ve
stem cell population resulted in increased Egfr and Lgr5
expression in vivo and intestinal tumors [12].
In addition to Egfr, the EGFR/Ras expression signature
induced by TGF-b1 in GIF-14 cells consisted of other positive
TGF-b-Induced Stemness Is Mediated via EGFR/Ras
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and negative regulators of the EGFR/Ras pathway, such as KRas
and Lrig1, respectively. It is likely that TGF-b1 activates an
EGFR/Ras expression program in GIF-14 cells en route to the
maintenance of a metastable stem cell-like state. This is
reminiscent to the reported cooperation between TGF-b and
Wnt pathways in GIF-14 cells that synergistically induced Lgr5, a
strong amplifier of the Wnt signal that supports normal and cancer
stem cells [8,12,16–18,35]. These observations suggest that TGF-
b, in addition to the phenotypic plasticity that it endows via EMT,
activates a series of genetic programs to promote a stem cell-like
state. It will be of great interest to determine if this pathway to
cellular plasticity and tumorigenicity involves additional signal
downstream of TGF-b1, EGFR and Wnt signaling; and if the
genetic circuits activated by these pathways are self-sustaining and
mutually enforcing.
In GIF-14 cells, the passage through TGF-b1-induced EMT is
marked by an acquisition of stem cell-like property, a process that
is hitherto tightly coupled to the induction of mesenchymal and
EMT-associated marker genes [18]. A key observation of the
current study is that KRas-induced stemness was not accompanied
by EMT, as reflected in an unaltered EMT/mesenchymal gene
expression signature. This revealed an unexpected uncoupling in
the induction of stemness and EMT in GIF-14 cells, providing
evidence that they are driven by distinct, though coordinated
cellular signals. Although the EGFR/Ras pathway is known to
promote EMT-like phenotypes in mammary epithelial cells [4,36];
hepatocytes [37,38] and lung epithelial cells [39], the insufficiency
of KRas to trigger an EMT in GIF-14 cells suggests that other
signaling modules downstream of TGF-b1 are requisite. This is
supported by the effective abrogation of EMT by a TGF-bR1
inhibitor (data not shown).
Lastly, EMT-induced stemness and tumorigenicity is a property
restricted to Runx32/2p532/2 fetal gastric epithelial lines and not
their Runx3+/+p532/2 counterparts, which reflects a safeguarding
function of Runx3 against cellular plasticity [18,19,40]. Consistent
with our observation that Hmga2 is a marker of TGF-b1/EGF-
induced plasticity in GIF-14 cells, a recent study reports a
surprising activation of a latent gastric differentiation program
during KRas-driven lung tumorigenesis that is marked by the
expression of Hmga2 [24]. In the same model, tissue-specific
ablation of Runx3 in lung epithelial cells greatly accelerated
KRasV12-driven lung carcinogenesis (SC Bae, pers comm.).
Collectively, these observations suggest that Runx3 serves as an
important tumor suppressor against Ras-induced tumorigenicity
by safeguarding against Hmga2-mediated plasticity and stemness.
Therefore, it will be of future interest to determine the
contribution of Runx3 in suppressing EGFR/Ras-mediated
stemness and tumorigenicity in GIF-14 cells.
Materials and Methods
Cell culture and treatment
The murine gastric epithelial cell line GIF-14 was established
from Runx32/2p532/2 fetal mouse stomachs [Fukamachi, 2004].
These cells were maintained in Dulbecco’s Modified Eagle
Figure 4. Proposed model for the contribution of EGFR/Ras/
MEK signaling pathway to TGF-b1-induced stemness and
tumorigenicity. The activation of TGF-b pathway triggers Runx32/2
p532/2 GIF-14 gastric epithelial cells into EMT, concurrently inducing a
stem cell-like and tumorigenic state. The data presented in this report
show that TGF-b1 induces an EGFR/Ras gene expression signature
marked by increased Egfr expression, which sensitized GIF-14 cells to
EGF. The activation of EGFR/Ras pathway promotes stemness and
tumorigenicity in GIF-14 cells in a MEK1/2-dependent manner that did
not involve increased EMT.
doi:10.1371/journal.pone.0070427.g004
Figure 3. KRas robustly induces stemness and tumorigenicity in GIF-14 cells without triggering EMT. (A) Wild type (KRasWT) or
oncogenic (KRasV12) KRas were induced for 48 h in pooled GIF-14/KRasWT and GIF-14/KRasV12 cells by the withdrawal of doxycycline (100 ng/ml).
Expression levels EMT/mesenchymal and stemness markers were determined by qRT-PCR, normalized against Gapdh levels and presented relative to
those of KRasWT uninduced sample (means 6 SEM, n = 3). Student’s t-tests are performed where indicated. Single and double asterisks denote p
value,0.05 and p value,0.01, respectively. (B) The effects of KRasV12 activation on the expression of mesenchymal and epithelial markers. Changes
in the expression levels of mesenchymal marker, Vimentin and epithelial marker, E-cadherin (E-Cad) upon the withdrawal of doxycycline (100 ng/ml)
for 24 h and 48 h in GIF-14/KRasV12 cells were measured by Western blot analysis. The expression levels of phosphorylated Erk1/2 were determined
to indicate the activation of Ras signaling pathway. Immunoblotting of a-tubulin serves as a control for the amount of proteins loaded. (C) The
activation of KRas has no discernable effect on cell morphology of GIF-14/KRasV12 cells 48 h after doxycycline (100 ng/ml) was withdrawn, compared
with those treated with TGF-b1 (2.5 ng/ml). Phase contrast images were captured. Scale bars = 50 mm. (D) The activation of KRas does not
significantly alter the migratory properties of GIF-14 cells. GIF-14/KRasV12 cells were concurrently induced for KRas expression and co-treated with
TGF-b1 (2.5 ng/ml) or carrier control for 24 h before the creation of scratch wounds. Phase contrast images were captured at 0 h and 12 h and
representative pictures 12 h post-wounding are shown. Scale bars = 50 mm. (E) Graphical representation of wound healing assay data as analysed by
the Tscratch software. Results presented are compiled from four replicates (means6 SEM, n= 4). Student’s t-tests are performed and double asterisks
denote p value,0.01 while n.s represents not significant. (F) KRasV12 promotes sphere formation in GIF-14 cells. Sphere-forming potentials of GIF-14/
KRasV12 cells were determined upon the activation of KRasV12 in the presence of SB431542 (10 mM) or U0126 (10 mM). Representative images of the
spheres are shown. Scale bars = 50 mm. (G) Graphical presentation of sphere assay results. The number of spheres $250 mm in size were scored after
6 days (means 6 SEM, n= 3). Student’s t-tests are performed. Single and double asterisks denote p value,0.05 and p value,0.01, respectively, (H)
Anchorage-independent growth of GIF-14/KRasV12 cells was ascertained by soft agar assay following the induction of KRasV12. Representative
images of the colonies at the seeding density of 200,000 cells/well are shown. Scale bars = 100 mm. (I) Graphical presentation of colony counts of soft
agar assays in which each replicate was seeded at 200,000 cells/well and cultured for 2 weeks (mean 6 SEM, n = 3). Student’s t-tests are performed
and double asterisks denote p-value,0.01.
doi:10.1371/journal.pone.0070427.g003
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Medium (DMEM; Invitrogen, CA, USA) with 4500 mg/l glucose
supplemented with 10% FBS, 100 units/ml penicillin and 100 mg/
ml streptomycin (Thermo Scientific Hyclone, UT, USA), in a 5%
CO2 incubator at 37uC. To activate various growth receptor
pathways, GIF-14 cells were treated with recombinant murine
epidermal growth factor (EGF; 10 ng/ml; PeproTech, NJ, USA);
human EGF (10 ng/ml; PeproTech), fibroblast growth factor
(FGF)-2 (10 ng/ml; PeproTech); FGF-10 (10 ng/ml; PeproTech),
hepatocyte growth factor (10 ng/ml; a gift from Jean Paul Thiery)
and transforming growth factor-beta 1 (TGF-b1; 2.5 ng/ml; R&D
Systems, MN, USA) for the time periods indicated. Inhibition of
TGF-bRI, EGFR and MEK1/2 were achieved by treatment with
SB431542 (10 mM in DMSO; TOCRIS Bioscience, Bristol, UK),
AG1478 (10 mM in DMSO; TOCRIS Biosciences) and U0126
(10 mM in DMSO; TOCRIS Biosciences), respectively.
Expression microarray analysis
Pre-EMT GIF-14 cells were treated with 2.5 ng/ml of
recombinant TGF-b1 (R&D Systems) for 24 h. Total RNA was
extracted from biological triplicates of TGF-b1-treated and
untreated cells using QIAGEN RNeasy Mini Kit (QIAGEN,
Hilden, Germany). Illumina TotalPrep RNA Amplification Kit
(Ambion, TX, USA) was utilized to amplify and biotin-label
500 ng of RNA prior hybridization to MouseRef-8 Gene
Expression BeadChip version 2 (Illumina, CA, USA). The raw
data was pre-processed by Illumina GenomeStudio Gene Expres-
sion module version 1.9 using quantile and average normalization
methods with default parameter settings. The data was log2
transformed for downstream analysis. Statistical Analysis of
Microarrays (SAM) was applied on the normalized data to identify
differentially expressed genes (q-value,0.05) [41]. To identify
pathways enriched in TGF-b1-treated cells, Gene Set Enrichment
Analysis (GSEA) was performed and pathways with nominal p-
values smaller than 0.05 were selected [42]. Log-average
expression of leading-edge genes was utilized to compute the
sample enrichment scores of various pathways to the microarray
data [43]. Raw microarray data have been deposited to the Gene
Expression Omnibus (Accession Number GSE44055).
Gene expression profiling by quantitative RT-PCR
Parental or derived lines of GIF-14 cells were cultured and
treated in 48-well plates. RNA extraction was performed using the
iScript RT-qPCR Sample Preparation Reagent (Bio-Rad, CA,
USA). The syntheses of cDNA were performed with the iScript
Reverse Transcription Supermix for RT-qPCR (Bio-Rad). Quan-
titative PCR was performed with gene-specific oligonucleotide
primers using SsoFast EvaGreen Supermix (Biorad) or Kapa
SYBR Fast Universal qPCR Master Mix (Kapa Biosystems, MA,
USA); or with Taqman probes (Applied Biosystems, CA, USA)
using SsoFast Probes Supermix (Bio-Rad) on a Applied Biosystems
7500 real-time PCR system (Applied Biosystems). A complete list
of the oligonucleotide primer sequences and Taqman probes used
are provided in Table 1. Unless otherwise stated, all gene
expression data were normalized against Gapdh levels.
Soft agar colony assay
GIF-14/KRasV12 cells were suspended in 0.4% agarose and
DMEM supplemented with 10% FBS and seeded over a basal
layer of 0.6% agarose. The experiments were set up in 6-well
plates at cell densities of 200,000 and 500,000 cells/well in
triplicates. Colonies were scored manually after 2 weeks of culture
at 37uC. Phase contrast micrographs of the colonies were captured
on an Olympus SZX12 microscope (Olympus, Tokyo, Japan).
Sphere-forming assay
GIF-14/KRasV12 cells were seeded at a density of 5000 cells/
well in 6-well ultra-low attachment plates (Sigma-Aldrich, MO,
USA) and cultured in serum-free DMEM:F12 medium (Invitro-
gen) containing 20 ng/ml human recombinant EGF (PeproTech),
10 ng/ml human recombinant FGF-2 (PeproTech), B27 (Invitro-
gen), N2 (Invitrogen), 1 ng/ml hydrocortisone (StemCell Tech-
nologies, CA, USA), 5 ug/ml insulin (Invitrogen) and 0.4% BSA
Table 1. Oligonucleotide primers and Taqman probes used for quantitative RT-PCR.
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Fraction V (Sigma-Aldrich). Methylcellulose (Sigma-Aldrich) was
added to prevent cell aggregation to a final concentration of 0.5%,
unless otherwise stated. At the indicated time, the number of
spheres of the indicated sizes were counted and imaged under
phase contrast microscopy performed on a Nikon Eclipse TS100
(Nikon, Tokyo, Japan).
Virus production and transduction
The pRevTRE-KRas and pRevTre-KRasV12 and pBABE-
puro-tTA (Tet-off) retroviral constructs were kindly provided by
Drs. Matthias Drosten and Mariano Barbacid (CNIO; Madrid,
Spain) [44]. pRev- and pBABE-based transfer vectors were co-
transfected with the ecotropic helper retrovirus plasmid pCL-Eco
(a gift from Motomi Osato) into HEK 293T cells using FuGENE
HD (Roche, Basel, Switzerland). Supernatants containing viral
particles were harvested 36 h and 48 h post-transfection and
pooled. For transduction with retroviruses, GIF-14 cells were
incubated with virus-containing supernatants in the presence of
5 mg/ml polybrene (Sigma-Aldrich) for 24 h before replenishment
with normal culture medium. Cells were then subjected to
puromycin (5 mg/ml; Invitrogen) or/and hygromycin (800 mg/
ml; Invitrogen) selection and maintained in the presence of
doxycycline (100 ng/ml; Clontech, CA, USA). Wild type and the
oncogenic form of KRas were activated for 24 or 48 h by
doxycycline withdrawal prior to direct lysis for RNA extraction
and gene expression profiling.
Western blot analysis
GIF-14 cells treated with TGF-b1 or EGF for the indicated time
periods or GIF-14/KRasV12 cells were harvested for Western
blot analysis. Cell pellets were lysed by RIPA buffer (50 mM Tris-
HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxy-
cholate and 1 mM EDTA) and whole cell lysates were resolved in
6% or 10% SDS-polyacrylamide gels. Murine total Egfr was
detected using two separate anti-Egfr antibodies – Ab2430 (1:200
dilution; Abcam, Cambridge, UK; a gift from Amy Lau Yong
Chen and Peter Lobie) and #2232 (1:1000 dilution; Cell
Signaling, MA, USA; a gift from Manoj Garg and H. Phillip
Koeffler). Immunoblotting with anti-phosphorylated Egfr (Eg-
frY1068 and EgfrY1092; 1:1000 dilution; Abcam), anti-Erk1/2
(1:1000 dilution; BD Transduction Laboratories, NJ, USA), anti-
phosphorylated Erk1/2 (1:1000 dilution; Cell Signaling), anti-E-
Cadherin (1:1000 dilution; Abcam), anti-Vimentin (1:500 dilution;
Abcam), anti-a-tubulin (1:10000 dilution; Sigma-Aldrich), anti-
mouse IgG-HRP (1:3000 dilution; GE Healthcare, Buckingham-
shire, UK), anti-Rabbit IgG HRP (1:3000 dilution; GE Health-
care) and anti-rat IgG HRP (1:3000 dilution; Dako, Glostrup,
Denmark) antibodies were performed.
Wound healing assay
KRasV12 was activated in GIF-14/KRasV12 cells and
concurrent treatment with TGF-b1 for 24 h was performed. Cells
were grown to confluence in 6-cm dishes and wounds were
generated using 200 p pipette tips. Phase contrast images were
captured at 0 h and 12 h. For each sample, 4 images were taken
from 3 wounds and the imaging data was analysed by the Tscratch
software [45].
Densitometric analysis
The intensities of protein bands from Western blots were
determined using Adobe Photoshop CS3 software. Three different
samplings were performed and the band intensities were
normalized against those of a-tubulin.
Statistical analysis
All data are presented as the means6 SEM. Student’s t-test was
utilized in the comparisons of two data sets, and p value,0.05
were considered significant.
Supporting Information
Figure S1 TGF-b1 and EGF cooperate to induce Hmga2
in GIF-14 cells. The effects of various growth factor treatment
on the gene expression of stemness- and EMT/mesenchymal-
associated markers. GIF-14 cells were treated with murine EGF
(mEGF; 10 ng/ml), human EGF (hEGF; 10 ng/ml), FGF2
(10 ng/ml), FGF10 (10 ng/ml) or HGF (10 ng/ml) in isolation
or in combination with TGF-b1 (2.5 ng/ml) for 24 h. Changes in
the gene expression levels were measured by qRT-PCR. The
values are normalized against Gapdh levels and expressed relative
to the control sample.
(TIF)
Figure S2 Phosphorylation of Erk is blocked by a
MEK1/2 inhibitor in TGF-b1- or KRasV12-activated
cells. GIF-14 cells were treated with TGF-b1 (2.5 ng/ml) while
GIF-14/KRasV12 cells were induced for KRasV12 activation in
the presence of U0126 (10 mM) for 24 h and 48 h. The expression
levels of phosphorylated Erk1/2 were assessed by Western blot
analysis and immunoblots of a-tubulin is used as a control for the
amount of proteins loaded.
(TIF)
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